Abstract:Objective: Identify novel mutations in FALS and SALS by whole exome sequencing. Background: 90[percnt] of ALS cases are defined as sporadic and 10[percnt] are defined as familial. Our goal is to classify ALS patients by their genotypes and to discover common functional pathways and pathologies which could be used to formulate strategies to stop or slow down the progression of disease. Exome sequencing was used to identify novel mutations. This technique led to discovery of novel mutations in ALS. Methods: This study was approved by the IRB. Clinical data were collected by qualified specialists and by examination of medical records. DNA and other samples were taken after obtaining written informed consent. DNA samples from 300 subjects were used for Exome Sequencing. Samples were prepared using we used Agilent Sure-Select Kit. Illumina HiSeq 2500 was used for sequencing. The average read per targeted base was >65X with the quality score of ≥30. Open source bioinformatics tools and in house written scripts were used to perform Bioinformatics. Validation of common SNPs was conducted using NCBI dbSNP and Exome Variant Server. Results: The data were separated into three categories, novel mutations within the coding regions, novel mutations outside of the coding regions and mutations in dbSNP. The average number of variants per sample was between 350,000 and 420,000. All of the samples were Sanger sequenced for the variance verified as mutations. Conclusions: Using NGS we have identified novel mutations in CHCHD10, R15L, HNRNPA1 (P288S), PFN1 (C71G) was identified in several families. A correlation between the depth and the number of SNPs has been found using linear regression. No correlation between the onset, disease duration and gender has been identified using Ordinal Linear Regression. Using NGS we have identified mutations in three other novel genes in ALS which are currently being tested for functionality. Disclosure: Dr. ahmeti has nothing to disclose. Dr. Ahmeti has nothing to disclose. Dr. Yan has nothing to disclose. Dr. Fecto has nothing to disclose. Dr. Siddique has nothing to disclose. Dr. Pericak-Vance has received personal compensation for activities with the University of Alaska as a scientific advisory board member. Dr. Deng has nothing to disclose. Dr. Siddique has nothing to disclose.

Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein

Publisher Correction: Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein

Whole-exome Sequencing in Amyotrophic Lateral Sclerosis Suggests NEK1 is a Risk Gene in Chinese

DnaJC7 in Amyotrophic Lateral Sclerosis

Whole Exome Sequencing of Familial ALS and Trios of Sporadic ALS to Identify New Genes Associated with ALS (P5.047)

The ALS-associated co-chaperone DNAJC7 mediates neuroprotection against proteotoxic stress by modulating HSF1 activity

Mutation Spectrum of Chinese Patients with Familial and Sporadic Amyotrophic Lateral Sclerosis

A Genome-wide Expression Association Analysis Identifies Genes and Pathways Associated with Amyotrophic Lateral Sclerosis

Validation of the pathogenic role of rare DNAJC7 variants in Chinese patients with amyotrophic lateral sclerosis

Rare DNAJC7 Variants May Play a Minor Role in Chinese Patients with ALS.

Functional identification of protocadherin alpha 9 (PCDHA9) as a candidate causative gene for amyotrophic lateral sclerosis

Validation of the pathogenic role of rare <i>DNAJC7</i> variants in Chinese patients with amyotrophic lateral sclerosis

Identify Mutation in Amyotrophic Lateral Sclerosis Cases Using HaloPlex Target Enrichment System

Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3′UTR protect against ALS

Integrative genetic analysis illuminates ALS heritability and identifies risk genes

Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis

PCDHA9 as a candidate gene for amyotrophic lateral sclerosis

DNA methylome, R-loop and clinical exome profiling of patients with sporadic amyotrophic lateral sclerosis

Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene

Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways

Amyotrophic Lateral Sclerosis Genetic Studies